Cardioprotective effects of trimetazidine: a review

References

• Berdeaux A, Colin P. Therapeutic perspectives in the treatment of stable angina. Therapie 2001;56(5):601–5
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Abrams J, Marks RG, Morris JJ, Scheidt SS, Handberg E. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol 1994;74(3):226–31
   PubMed Web of Science ®Google Scholar
• Kantor P, Lucien A, Kozak R, Lopaschuk G. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86(5):580–8
   PubMed Web of Science ®Google Scholar
• Jackson G. Combination therapy in angina: a review of combined hemodynamic treatment and the role for combined hemodynamic and cardiac metabolic agents. Int J Clin Pract 2001;55(4):256–61
   PubMed Web of Science ®Google Scholar
• Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994;37(3):279–88
   Google Scholar
• Marzilli M. Clinical benefits of a metabolic approach in the management of coronary patients. Rev Port Cardiol 2000;19(Suppl 5):V25–30
   Google Scholar
• Sellier P, Broustet JP. Efficacy at trough and safety of trimetazi-dine MR 35mg in patients with stable angina pectoris. Cardiovasc Drugs Ther 2001;15(Suppl):81
   Google Scholar
• Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990;11:207–12
   PubMed Web of Science ®Google Scholar
• Kober G, Pennaforte S, Buck T, Sievert H, Vallbracht C. Myocardial cytoprotection during percutaneous transluminal coronary angioplasty. Eur Heart J 1993;14(Suppl G):6–11
   PubMed Web of Science ®Google Scholar
• Tünerir B, Colak O, Alatas O, Besogul Y, Kural T, Aslan R. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann Thorac Surg 1999;68(6):2173–6
   PubMed Web of Science ®Google Scholar
• Lu C. Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998;82(7):898–901
   PubMed Web of Science ®Google Scholar
• Belardinelli R. Trimetazidine and the contractile response of dys-functional myocardium in ischaemic cardiomyopathy. Rev Port Cardiol 2000;19(Suppl 5):V35–9
   Google Scholar
• Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians’ perspective. Heart Fail Rev 2002;7(2):187–203
   PubMedGoogle Scholar
• Lopaschuk GD, Belke DD, Gamble J, Itoi I, Schönekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1994;1213:263–76
   PubMed Web of Science ®Google Scholar
• Opie L. The mechanism of myocytes death in ischemia. Eur Heart J 1993;14(Suppl G):31–3
   PubMedGoogle Scholar
• Stanley WC Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 2002;11(5):615–29
   PubMed Web of Science ®Google Scholar
• Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischemic heart disease: the pharmacology of trimetazidine. Fund Clin Pharmacol 2003;17:133–45
   PubMed Web of Science ®Google Scholar
• Mody FV, Singh BN, Mohiuddin IH, Coyle KB, Buxton DB, Hansen HW, Sumida R, Schelbert HR. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998;82(5A):42–9K
   Google Scholar
• El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, Feuvray D. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low-and zero-flow ischaemia. Cardiovasc Res 2000;47(4):688–96
   Google Scholar
• Sentex E, Sergiel JP, Lucien A, Grynberg A. Trimetazidine increases phospholipid turnover in ventricular myocyte. Mol Cell Biochem 1997;175:153–62
   PubMed Web of Science ®Google Scholar
• Sentex E, Helies-Toussaint C, Rousseau D, Lucien A, Ferrary E, Grynberg A. Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs. Fundam Clin Pharmacol 2001;15(4):255–64
   PubMed Web of Science ®Google Scholar
• Tabbi-Anneni I, Lucien A, Grynberg A. Trimetazidine effect on phospholipids synthesis in ventricular myocyte: consequences in a-adrenergic signalling. Fund Clin Pharmacol 2003;17:51–9
   PubMed Web of Science ®Google Scholar
• Ruiz-Meana M, Garcia-Dorado D, Julia M, Gonzalez MA, Inserte J, Soler-Soler J. Pre-treatment with trimetazidine increases sarcolemmal mechanical resistance in reoxygenated myocytes. Cardiovasc Res 1996;32(3):587–92
   PubMed Web of Science ®Google Scholar
• Di Pasquale P, Lo Verso P, Bucca V, Cannizzaro S, Scalzo S, Maringhini G, Rizzo R, Paterna S. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 1999;13(5):423–8
   PubMed Web of Science ®Google Scholar
• Lagadic-Gossman D, Le Prigent K, Feuvray D. Effects of trimetazidine on pHi, regulation in the rat isolated ventricular myocyte. Br J Pharmacol 1996;117:831–8
   PubMed Web of Science ®Google Scholar
• Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949–58
   PubMed Web of Science ®Google Scholar
• Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993;22(6):828–33
   PubMed Web of Science ®Google Scholar
• Belcher PR, Drake-Holland AJ, Hynd JW, Noble MI. Effects of trimetazidine on in vivo coronary arterial platelet thrombosis. Cardiovasc Drugs Ther 1993;7(1):149–57
   PubMed Web of Science ®Google Scholar
• Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: 31P NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987;286: 97–110
   PubMedGoogle Scholar
• Aussedat J, Ray A, Kay L, Verdys M, Harpey C, Rossi A. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993;21(1):128–35
   PubMed Web of Science ®Google Scholar
• Allibardi S, Chierchia SL, Margonato V, Merati G, Neri G, Dell’Antonio G, Samaja M. Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. Cardiovasc Drugs Ther 1998;12(6):543–9
   PubMed Web of Science ®Google Scholar
• Boucher FR, Hearse DJ, Opie LH. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol 1994;24(1):45–9
   PubMed Web of Science ®Google Scholar
• Drake-Holland AJ, Belcher PR, Hynd J, Noble MI. Infarct size in rabbits: a modified method illustrated by the effects of propranolol and trimetazidine. Basic Res Cardiol 1993;88(3):250–8
   PubMed Web of Science ®Google Scholar
• Guarnieri C, Finelli C, Zini M, Muscari C. Effects of trimetazi-dine on the calcium transport and oxidative phosphorylation of isolated rat heart mitochondria. Basic Res Cardiol 1997;92 (2):90–5
   PubMed Web of Science ®Google Scholar
• D’Hahan N, Taouil K, Janmot C, Morel JE. Effect of trimetazi-dine and verapamil on the cardiomyopathic hamster myosin phenotype. Br J Pharmacol 1998;123(4):611–16
   PubMed Web of Science ®Google Scholar
• Devynck MA, Le Quan Sang KH, Joulin Y, Mazeaud M. Inhibitory effect of trimetazidine on thrombin-induced aggregation and calcium entry into human platelets. J Cardiovasc Pharmacol 1994;23(3):401–7
   PubMed Web of Science ®Google Scholar
• Maupoil V, Rochette L, Tabard A, Clauser P, Harpey C. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: effect of trimetazidine. Adv Exp Med Biol. 1990;264:373–6
   PubMedGoogle Scholar
• Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985;20:148–51
   PubMed Web of Science ®Google Scholar
• Pudil R, Pidrman V, Krejsek J, Gregor J, Tichy M, Andrys C, Drahosova M, Blaha V. The effect of trimetazidine on C-reactive protein, cytokines and adhesion molecules in the course of acute myocardial infarction. Acta Medica (Hradec Kralove) 2001;44(4):135–40
   PubMedGoogle Scholar
• Willoughby SR, Chirkov YY, Kennedy JA, Murphy GA, Chirkova LP, Horowitz JD. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses. Eur J Pharmacol 1998;356(2–3):207–13
   Google Scholar
• Shirahase H, Suzuki Y, Osumi S, Kakeya N, Kurahashi K. Inhibitory effects of trimetazidine dihydrochloride on aggregation, serotonin release and malondialdehyde production in rabbit platelets. Jpn J Pharmacol 1988;47(1):29–34
   PubMedGoogle Scholar
• Desideri A, Celegon L, Metabolic management of ischemic heart disease: clinical data with trimetazidine. Am J Cardiol 1998;82 (5A):50–3K
   PubMedGoogle Scholar
• Cross HR. Trimetazidine for stable angina pectoris. Expert Opin Pharmacother 2001;2(5):857–75
   PubMedGoogle Scholar
• Jackson G. Stable angina: maximal medical therapy is not the same as optimal medical therapy. Int J Clin Pract 2000;54(6):351
   PubMed Web of Science ®Google Scholar
• Marzilli M, Klein W. Efficacy and tolerability of trimetazidine in stable angina: a metaanalysis of randomized, double-blind, controlled trials. Cor Artery Dis 2003;14:171–9
   PubMed Web of Science ®Google Scholar
• Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina: controlled multicenter double blind versus placebo study. Arch Mal Coeur Vaiss 1986;79:1331–6
   PubMedGoogle Scholar
• Passeron J. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency: a double-blind versus placebo study. Presse Med 1986;15:1775–8
   PubMedGoogle Scholar
• Gallet M. Clinical effectiveness of trimetazidine in stable effort angina: a double blind versus placebo controlled study. Presse Med 1986;15:1779–82
   PubMed Web of Science ®Google Scholar
• Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipene in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990;4:853–9
   PubMed Web of Science ®Google Scholar
• Levy S, Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol 1995;76:12–16B
   Google Scholar
• Manchanda SC, Krishnaswani S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997;78:353–7
   PubMed Web of Science ®Google Scholar
• Szwed H, Sadowski Z, Elikowski W, KoronKiewizc A, et al. Trimpol II: combination treatment of stable effort angina using trimetazidine and metoprolol: results of a randomised, double iblind, multicentre study. Eur Heart J 2001;22(2):2267–74
   PubMedGoogle Scholar
• Piot C. Metabolic considerations in the treatment of coronary disease in diabetic patients. Diabetes Metab 2001;27(5 Pt 2):S25–9
   Google Scholar
• Marzilli M. Management of ischemic heart disease in diabetic patients – is there a role for cardiac metabolic agents? Curr Med Res Opin 2001;17(3):153–8
   PubMed Web of Science ®Google Scholar
• Beygui F. Trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Rev Port Cardiol 2000;19(Suppl 5):V31–4
   Google Scholar
• Steg PG, Grollier G, Gallay P, et al. for the LIST Study Group. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 2001;77(2–3):263–73
   PubMed Web of Science ®Google Scholar
• Birand A, Kudaiberdieva GZ, Batyraliev TA, Akgul F, Usal A. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 1997;48(5):413–22
   PubMed Web of Science ®Google Scholar
• Polonski L, Dec I, Wojnar R, Wilczek K. Trimetazidine limits the effects of myocardial ischaemia during percutaneous coronary angioplasty. Curr Med Res Opin 2002;18(7):389–96
   PubMed Web of Science ®Google Scholar
• Triggiani M, Simeone F, Gallorini C, et al. Measurement of cardiac troponin T and myosin to detect perioperative myocardial damage during coronary surgery. Cardiovasc Surg 1994;2(4):441–5
   PubMedGoogle Scholar
• Vedrinne JM, Vedrinne C, Bompard D, Lehot JJ, Boissel JP, Champsaur G. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 1996;82(4):712–18
   PubMed Web of Science ®Google Scholar
• Fabiani JN, Ponzio O, Emerit I, Massonet-Castel S, Paris M, Chevalier P, Jebara V, Carpentier A. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg (Torino) 1992;33(4):486–91
   PubMedGoogle Scholar
• Di Girolamo E, Potere F, Sabatini P, Leonzio L, Barsotti A. A 201Tl scintigraphic evidence of trimetazidine-mediated improvement of coronary microcirculation in patients with chronic stable angina. J Am Coll Cardiol 2000;35(Suppl A):409
   Google Scholar
• Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001;22(23):2164–70
   PubMed Web of Science ®Google Scholar
• The EMIP-FR Group. European Myocardial Infarction Project-Free Radicals. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; double-blind, placebo-controlled, randomized trial. Eur Heart J 2000;21(18):1537–46
   PubMed Web of Science ®Google Scholar
• Papadopoulos CL, Kanonidis IE, Kotridis PS, Papayannis IL, Savatis SC, Missopoulou-Kokka AI, Nikolaidis NK, Koukoulekidis GN, Sakadamis GC. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Int J Cardiol 1996;26;55(2):137–42
   PubMed Web of Science ®Google Scholar
• Kountouris E, Pappa E, Pappas K, Dimitroula V, Karanikis P, Tzimas T, Siogas K. Metabolic management of coronary heart disease: adjunctive treatment with trimetazidine decreases QT dispersion in patients with a first acute myocardial infarction. Cardiovasc Drugs Ther 2001;15(4):315–21
   PubMed Web of Science ®Google Scholar
• Ozdemir R, Tuncer C, Aladag M, et al. Effect of trimetazidine on late potentials after acute myocardial infarction. Cardiovasc Drugs Ther 1999;13(2):145–9
   PubMed Web of Science ®Google Scholar
• Ulgen MS, Akdemir O, Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol 2001;77(2–3):255–62
   Google Scholar